Dear Pharma Forwarders,

The pharmaceutical landscape continues to morph at rapid pace, and participating companies are having to develop ever more sophisticated supply chain processes and strategies in order to deal with ongoing changes in demographics, urban migration, increasing demand for health care, shifts toward age related disease patterns, and a rising health awareness across the population. (One Network Enterprise, 2016)

According to Mark Millar, there are tons of reasons why emerging markets grow. In Asia Pacific we’ve got a couple of demographic issues on certain markets particularly in China and Japan, we have aging demographic, so that’s going to fuel up demands for more healthcare services and also as economy becomes genuinely more prosperous, health care becomes more affordable. In the recent years, there are a lot of trends that transforms the pharmaceutical supply chain.

Download Mark Millar’s digital presentation to be fully informed regarding the trends and developments in the pharma supply chain.

1. THE RISE OF OTC AND GENERICS

Competition from generics coupled with pressure from expiring patents gave flattened or decreased the top-line potential of many branded business units. From a supply chain perspective, this means that, like most other industries, pharmaceutical distribution channels must address the increased usage of online ordering and dire-to-customer delivery processes.

2. RISING HEALTHCARE COSTS
Aging populations are the key factor for growing cost pressures within many of the world’s most advanced health systems, as it continues to increase in numbers, the government welfare is obliged to pay for the healthcare services consumed by the elderly. Managing access to healthcare providers, pharmaceuticals, medical devices, and procedures will thus become an increasingly crucial factor for managing the cost of healthcare in industrialized countries.

3. INCREASED REGULATORY OVERSIGHT

Due to more complex supply chains, policy makers worldwide are enforcing stricter regulations for manufacturing and logistics. Hand in hand with GMP standards, governments and international organizations such as WHO, have established and increased their requirements for Good Distribution Practices (GDP) – these standards define how life sciences products, particularly pharmaceuticals, have to be stored, transported and handled. Key new requirements in the European Union include risk assessment of delivery routes, temperature monitoring and reporting of temperature excursions and the use of dedicated vehicles where possible.

Developing and maintaining the ability to adapt their supply chains, companies in the pharmaceutical sector will be well prepared to seize the opportunities ahead. Life Logistics Network provides the platform to enable top-class pharmaceutical forwarders to deliver specific needs that can be trusted only to companies with know-how in the business. Overall, it is best to consider joining a reliable network that will provide better ways to adapt to changing market conditions and improving compliance.

Source:

http://www.supplychain247.com/